

Attorney Docket : ANVIL.001BNP3
Appl. No. : Unknown
Filed : Herewith

AMENDMENTS TO THE CLAIMS

1.-24. (Canceled)

25. (Original) A prosthesis for placement at an Os opening from a main body lumen to a branch body lumen; the prosthesis comprising:

a radially expansible support, the support configured to be deployed in at least a portion of the branch body lumen; and

a plurality of fronds extending axially from an end of the support, the fronds configured to be deformably deployed in at least a portion of the main body lumen and to apply less radial force to adjacent tissue than the expanded support applies in the branch body lumen.

26.-29. (Canceled)

30. (New) The prosthesis of Claim 25, wherein the plurality of fronds includes at least three fronds.

31. (New) The prosthesis of Claim 25, wherein the plurality of fronds comprises a helical configuration.

32. (New) The prosthesis of Claim 31, comprising a plurality of helical fronds.

33. (New) The prosthesis of Claim 25, wherein at least a portion of the plurality of fronds comprises a lubricous coating.

34. (New) The prosthesis of Claim 25, comprising an endothelial cell ingrowth surface.

35. (New) The prosthesis of Claim 25, comprising a non thrombogenic surface.

36. (New) The prosthesis of Claim 25, further comprising a circumferential link that connects each of the plurality of fronds.

Attorney Docket : ANVIL.001BNP3
Appl. No. : Unknown
Filed : Herewith

37. (New) The prosthesis of Claim 36, wherein at least a portion of the radially expandible support comprises a drug coating, and at least a portion of the fronds and the circumferential link are without a drug coating.

38. (New) The prosthesis of Claim 37, wherein the drug coating is configured to produce at least one of a controlled drug release rate, a constant drug release rate, bi-modal drug release rate or a controlled concentration of drug proximate a target vessel wall.

39. (New) The prosthesis of Claim 37, wherein the drug is one of an anti-cell proliferative, anti cell migration, anti-neo plastic, anti inflammatory drug.

40. (New) The prosthesis of Claim 37, wherein the drug is configured to reduce an incidence or amount of restenosis.

41. (New) The prosthesis of Claim 37, wherein the drug coating includes a first coating and a second coating.

42. (New) The prosthesis of Claim 41, wherein the first coating is configured to produce a first drug release rate and the second coating is configured to produce a second drug release rate.

43. (New) The prosthesis of Claim 36, wherein the circumferential link is expandable from a first, reduced diameter to a second, enlarged diameter.

44. (New) The prosthesis of Claim 36, wherein the support is on a first end of at least one of the fronds, and the circumferential link is on a second end of at least one of the fronds.

45. (New) The prosthesis of Claim 36, wherein the circumferential link is radiopaque.

46. (New) The prosthesis of Claim 36, wherein the circumferential link has a greater radiopacity than the frond.